Zynerba starts Ph I study of cannabinoid pain patch
Zynerba Pharmaceuticals Inc has begun a Phase I trial of cannabinoid patch it is developing for fibromyalgia and peripheral neuropathic pain.
The study – details of which were provided in a US Securities and Exchange Commission (SEC) filing - will examine the safety and tolerability of ZYN001, which is a pro-drug of tetrahydrocannabinol (THC) that is delivered using a transdermal patch.
ZYN001 is the second Zynerba transdermal, cannabinoid based product in clinical development after ZYN002, a synthetic cannabidiol (CBD) formulated as a permeation-enhanced gel for application to the skin.
The drug, which is being developed to treat epilepsy, is being examined in a Phase I study in Australia, in collaboration with contract research organisation (CRO) Novotech.
